BIRC3 mutation
|
Small Lymphocytic Lymphoma
|
BIRC3 mutation
|
Small Lymphocytic Lymphoma
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
BIRC3 mutation
|
CLL
|
BIRC3 mutation
|
CLL
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
BIRC3 mutation
|
CLL
|
BIRC3 mutation
|
CLL
|
obinutuzumab Resistant: B - Late Trials
|
obinutuzumab Resistant: B - Late Trials
|
BIRC3 mutation
|
CLL
|
BIRC3 mutation
|
CLL
|
rituximab Resistant: C3 – Early Trials
|
rituximab Resistant: C3 – Early Trials
|
BIRC3 mutation
|
Mantle Cell Lymphoma
|
BIRC3 mutation
|
Mantle Cell Lymphoma
|
temsirolimus Resistant: C3 – Early Trials
|
temsirolimus Resistant: C3 – Early Trials
|
BIRC3 mutation
|
CLL
|
BIRC3 mutation
|
CLL
|
FCR Resistant: C3 – Early Trials
|
FCR Resistant: C3 – Early Trials
|
BIRC3 mutation
|
CLL
|
BIRC3 mutation
|
CLL
|
BR Resistant: C3 – Early Trials
|
BR Resistant: C3 – Early Trials
|
BIRC3 mutation
|
CLL
|
BIRC3 mutation
|
CLL
|
DC-1-192 Sensitive: D – Preclinical
|
DC-1-192 Sensitive: D – Preclinical
|